EC 257-139-7
Also known as TARPEYO.
Brings acquired specialty-pharma units into a single global management to pursue niche immunology, nephrology, transplant and infectious disease markets; targets ¥300bn by FY2030.
Nefecon's inclusion in KDIGO 2025 guidelines highlights its role in IgAN treatment, supporting Asahi Kasei's strategic growth in healthcare.
